Skip to main content
OpenTrials
Completed

NCT Number: NCT06484634

Role of Low-Molecular-Weight Heparin in Unexplained Recurrent Pregnancy Loss

Using low-molecular-weight heparin (LMWH), outcomes such as live birth rate and the occurrence of pregnancy complications are some of the variables reported in some studies, with varying degrees of success. The present study aimed to compare the role of LMWH in unexplained recurrent pregnancy loss.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pregnancy Loss

Age range

18 year–44 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

DG Khan Hospital

Dera Ghazi Khan, Punjab Province, 32200, Pakistan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pregnant females between 18 and 44 years of age
  • Gestational age above 8 weeks
  • A history of ≥3 consecutive first trimester pregnancy losses

Exclusion criteria

  • Patients with systemic lupus erythematosus
  • Positive IgG and IgM anticardiolipin antibodies
  • Positive for thrombophilia screening
  • Any platelet function abnormality or a previous thromboembolic event requiring anticoagulant therapy (including heparin, aspirin or warfarin)
  • Sensitive to acetylsalicylic acid, heparin, or warfarin
  • Patients with any genetic, anatomical, or hormonal cause of recurrent pregnancy loss

Treatment and study plan

Low molecular weight heparin

Drug

A daily dose of 40 mg of low-molecular-weight heparin (LMWH) subcutaneously was given to the patients.

Primary outcomes

  1. Efficacy of Low-Molecular-Weight Heparin

    Time frame: 32 weeks

    Efficacy was labeled as yes in terms of live births after the age of viability, i.e., 24 weeks of gestation.

Sponsors and collaborators

Lead sponsor

RESnTEC, Institute of Research

Other

Registry information

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Jul 3, 2024
Registry last updated
Jul 3, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.